The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa, MD, Levine Cancer Institute, Winston-Salem, NC, discusses the potential for treatment-free remission in patients with polycythemia vera (PV), including the role of long-acting interferons such as ropeginterferon in achieving molecular responses. He highlights the need for sustained molecular remission before considering treatment withdrawal and the potential for combination approaches to deepen responses in selected patients. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Treatment-free remission in PV, I think, remains aspirational. Certainly there are some data that I think will increase over time of individuals that truly have had a, you know, kind of molecular remission, if you would, particularly from the JAK2 mutation with long-acting interferons like ropeginterferon that certainly raise that point. I think some of that is dose-dependent, and we have seen, you know, in areas where there has been, I think, more aggressive dosing strategies are a bit more successful in that regard...
Treatment-free remission in PV, I think, remains aspirational. Certainly there are some data that I think will increase over time of individuals that truly have had a, you know, kind of molecular remission, if you would, particularly from the JAK2 mutation with long-acting interferons like ropeginterferon that certainly raise that point. I think some of that is dose-dependent, and we have seen, you know, in areas where there has been, I think, more aggressive dosing strategies are a bit more successful in that regard. I think I would want to see an individual at least have, you know, a solid, you know, year or two of molecular remission, you know, before trying to back off on that approach. You know, we’ve learned a lot from the CML experience. You know, however, in MPNs, I think our information still remains more limited. I am excited as we get into the type 2 JAK inhibitors and other agents that perhaps some combination of interferon and more powerful JAK inhibition may perhaps give us a broader group of individuals where we get a deeper set of responses to truly be able to have some sort of treatment-free remission for these individuals.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
